Abstract | BACKGROUND: Signal transducer and activator of transcription (STAT) 3 plays a vital role in carcinogenesis and drug response. Platinum-based chemotherapy is the first-line treatment for lung cancer patients, especially those in advanced stages. In the present study, we investigated the association of STAT3 polymorphism rs4796793 with lung cancer susceptibility, platinum-based chemotherapy response, and toxicity. METHODS: A total of 498 lung cancer patients and 213 healthy controls were enrolled in the study. 467 of them received at least 2-cycle platinum-based chemotherapy. Unconditional logistical regression analysis was used to assess the associations. RESULTS: STAT3 rs4769793 G allele carriers had an increased susceptibility of lung cancer [additive model: adjusted OR (95% CI) 1.376 (1.058-1.789), P = 0.017; recessive model: adjusted OR (95% CI) 1.734 (1.007-2.985), P = 0.047]. Rs4769793 was not significantly associated with platinum-based chemotherapy response in lung cancer patients. STAT3 rs4796793 was associated with an increased risk of severe overall toxicity [additive model: adjusted OR (95% CI) 1.410 (1.076-1.850), P = 0.013; dominant model: adjusted OR (95% CI) 1.638 (1.091-2.459), P = 0.017], especially hematological toxicity [additive model: adjusted OR (95% CI) 1.352 (1.001-1.826), P = 0.049]. CONCLUSIONS: STAT3 rs4796793 may be considered as a potential candidate biomarker for the prediction of susceptibility and prognosis in Chinese lung cancer patients. However, well-designed studies with larger sample sizes are required to verify the results.
|
Authors | Wei-Jing Gong, Li-Yun Ma, Lei Hu, Yong-Ning Lv, Hong Huang, Jia-Qiang Xu, Dan-Dan Huang, Rui-Jie Liu, Yong Han, Yu Zhang, Shao-Jun Shi, San-Lan Wu |
Journal | International journal of clinical oncology
(Int J Clin Oncol)
Vol. 24
Issue 5
Pg. 476-484
(May 2019)
ISSN: 1437-7772 [Electronic] Japan |
PMID | 30689078
(Publication Type: Journal Article, Meta-Analysis)
|
Chemical References |
- STAT3 Transcription Factor
- STAT3 protein, human
- Platinum
|
Topics |
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Asian People
(genetics)
- Case-Control Studies
- Female
- Genetic Predisposition to Disease
(genetics)
- Humans
- Lung Neoplasms
(drug therapy, genetics)
- Male
- Middle Aged
- Platinum
(pharmacology)
- Polymorphism, Single Nucleotide
- Prognosis
- STAT3 Transcription Factor
- Treatment Outcome
|